A dual MDM2/4 inhibitor, RS3594, and a CXCR4 antagonist, AMD3100, were used to treat human GBM cells and GBM stem-like cells and in addition to inhibiting neurosphere growth and inducing differentiation of GBM cells, AMD3100 and RS3594 demonstrated synergistic effects on cancer stem components (Daniele et al., 2021). This evidence concerns the gene CXCR4 and glioblastoma.